These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33547681)

  • 21. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
    Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
    Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM; Mato AR
    Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan.
    Nestorov I; Graham G; Duffull S; Aarons L; Fuseau E; Coates P
    Pharm Res; 2001 Aug; 18(8):1210-9. PubMed ID: 11587494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.
    Lamba M; Hutmacher MM; Furst DE; Dikranian A; Dowty ME; Conrado D; Stock T; Nduaka C; Cook J; Krishnaswami S
    Clin Pharmacol Ther; 2017 Jun; 101(6):745-753. PubMed ID: 27859030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of an innovative population pharmacokinetic-based design for behavioral pharmacodynamic endpoints.
    Viberg A; Martino G; Lessard E; Laird JM
    AAPS J; 2012 Dec; 14(4):657-63. PubMed ID: 22711220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.
    Janssen JM; Zwaan CM; Schellens JHM; Beijnen JH; Huitema ADR
    Eur J Cancer; 2017 Nov; 85():78-85. PubMed ID: 28892776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A quantitative mechanistic PK/PD model directly connects Btk target engagement and
    Daryaee F; Zhang Z; Gogarty KR; Li Y; Merino J; Fisher SL; Tonge PJ
    Chem Sci; 2017 May; 8(5):3434-3443. PubMed ID: 28507715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
    Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
    Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
    Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
    AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review.
    Loisios-Konstantinidis I; Paraiso RLM; Fotaki N; McAllister M; Cristofoletti R; Dressman J
    J Pharm Pharmacol; 2019 Apr; 71(4):699-723. PubMed ID: 30793317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
    Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
    Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.
    Ayyar VS; Jusko WJ
    Pharmacol Rev; 2020 Apr; 72(2):414-438. PubMed ID: 32123034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model.
    Iida H; Fujikawa R; Kozaki R; Harada R; Hosokawa Y; Ogawara KI; Ohno T
    J Pharmacol Exp Ther; 2020 Jun; 373(3):361-369. PubMed ID: 32217770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters.
    Smit C; De Hoogd S; Brüggemann RJM; Knibbe CAJ
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):275-285. PubMed ID: 29431542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translational PK-PD for targeted protein degradation.
    Bartlett DW; Gilbert AM
    Chem Soc Rev; 2022 May; 51(9):3477-3486. PubMed ID: 35438107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-Response-Time Data Analysis: An Underexploited Trinity.
    Gabrielsson J; Andersson R; Jirstrand M; Hjorth S
    Pharmacol Rev; 2019 Jan; 71(1):89-122. PubMed ID: 30587536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance Mechanisms.
    Leung L; Yang X; Strelevitz TJ; Montgomery J; Brown MF; Zientek MA; Banfield C; Gilbert AM; Thorarensen A; Dowty ME
    Drug Metab Dispos; 2017 Jan; 45(1):1-7. PubMed ID: 27784718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.
    Mahadevan D; Plummer R; Squires MS; Rensvold D; Kurtin S; Pretzinger C; Dragovich T; Adams J; Lock V; Smith DM; Von Hoff D; Calvert H
    Ann Oncol; 2011 Sep; 22(9):2137-2143. PubMed ID: 21325451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate.
    Ballard JE; Pall P; Vardigan J; Zhao F; Holahan MA; Kraus R; Li Y; Henze D; Houghton A; Burgey CS; Gibson C
    Pharm Res; 2020 Sep; 37(10):181. PubMed ID: 32888082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.